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Objective To compare the impact of 1000 micrograms of self-
administered vaginal misoprostol versus self-administered vaginal
placebo on preoperative cervical ripening after pre-treatment with
estradiol vaginal tablets at home in postmenopausal women prior
to day-care operative hysteroscopy.
Design Randomised double-blind placebo-controlled sequential
trial. The boundaries for the sequential trial were calculated on the
primary outcomes of a difference of cervical dilatation ‡1m i l l i m e t r e ,
with the assumption of a type 1 error of 0.05 and a power of 0.95.
Setting Norwegian university teaching hospital.
Population Postmenopausal women referred for day-care
operative hysteroscopy.
Methods The women were randomised to either 1000 micrograms
of self-administered vaginal misoprostol or self-administered
vaginal placebo the evening before day-care operative
hysteroscopy. All women had administered a 25-microgram
vaginal estradiol tablet daily for 14 days prior to the operation.
Main outcome measures Preoperative cervical dilatation
(difference between misoprostol and placebo group, primary
outcome), difference in dilatation before and after administration
of misoprostol or placebo, number of women who achieve
a preoperative cervical dilatation ‡5 millimetres, acceptability,
complications and side effects (secondary outcomes).
Results Intra-operative ﬁndings and distribution of cervical
dilatation in the two treatment groups: values are given as median
(range) or n (%). Difference in dilatation before and after
administration of misoprostol and placebo: values are given as
median (range) of intraindividual differences. Percentage of
women who achieve a cervical dilatation of ‡5 mm, percentage of
women who were difﬁcult to dilate. Acceptability in the two
treatment groups: values are given as completely acceptable n (%),
fairly acceptable n (%), fairly unacceptable n (%), completely
unacceptable n (%). Pain in the two treatment groups: pain was
measured with a visual analogue scale ranging from 0 (no pain) to
10 (unbearable pain): values are given as median (range).
Occurrence of side effects in the two treatment groups. Values are
given as n (%). Complications given as n (%).
Funding sources No pharmaceutical company was involved in this
study. A research grant from the regional research board of
Northern Norway has been awarded to ﬁnance Dr K.S.O.’s leave
from Hammerfest hospital as well as travel expenses between
Hammerfest and Oslo, and research courses. The research grant
from Prof B.I.N. (Helse Øst) funded the purchase of estradiol
tablets, the manufacturing costs of misoprostol and placebo
capsules from the hospital pharmacy, as well as the costs incurred
for preparing the randomisation schedule and distribution of
containers containing capsules to hospital. Prof B.I.N.’s research
grant also funded insurance for the study participants.
Conclusions Estimated completion date 31 December 2008.
Keywords Cervical ripening, estradiol, hysteroscopy, misoprostol,
postmenopausal.
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Over the past 20 years, minimally invasive operative techni-
ques have been introduced for treating intrauterine pathol-
ogy. Operative hysteroscopy or resectoscopy is currently
the most common method in the industrialised world for
treating intrauterine pathology, such as leiomyomas and
endometrial polyps. Endometrial resection is a standard
treatment for abnormal uterine bleeding, if less invasive
procedures fail.1 The diameter of resectoscopes (usually
Charriere 24 or 26) necessitate dilatation of the cervical
canal to 10 or 11 millimetres prior to insertion of the instru-
ment. The possible complications encountered during dila-
tation, such as cervical tears, creation of false passages and
uterine perforation are reported to be mainly related to dif-
ﬁculty of cervical dilatation in nulliparous and postmeno-
pausal women.2 An audit of women who have undergone
operative hysteroscopy in our department supports this,3
showing a complication rate of 7.8% related to hysteroscopic
resection of endometrial polyps. In our recent study4 the
frequency of complications during operative hysteroscopy
was 11% and occurred mostly in nulliparous premenopausal
or postmenopausal women. Experienced gynaecologists
judged 42% of dilatations in postmenopausal women to be
difﬁcult.
Reduction in incidence of cervical injury and uterine
perforation during termination of pregnancy has been
demonstrated by preoperative cervical ripening5,6 and
may be achieved either mechanically, with osmotic dila-
tors,7 or biochemically with prostaglandins.8 Locally
applied prostaglandins are an inexpensive and resource-
saving method of achieving cervical ripening compared
with osmotic dilators, particularly if women are able to
insert the tablets vaginally themselves at home prior to their
operation. Misoprostol is a synthetic prostaglandin E2 ana-
l o g u et h a ti sw i d e l yu s e df o rt h i sp u r p o s ea si ti si n e x p e n -
sive and effective.8,9 Misoprostol appears to be effective for
cervical ripening in nonpregnant premenopausal women
prior to hysteroscopy.10 Further research in postmeno-
pausal women has been recommended, to determine
whether misoprostol is effective in cervical ripening in this
population. We found six reported randomised controlled
trials published in English (Appendix 1,2) that evaluated
the efﬁcacy of misoprostol on cervical ripening on post-
menopausal women published before 31 October 2007,
after searching medical literature databases including
Pubmed11 and EMBASE Ovid.12 The search terms used
included ‘misoprostol’, ‘cervical ripening/priming’ ‘hys-
teroscopy’, and ‘operative hysteroscopy’. References from
identiﬁed publications were manually searched and cross-
referenced to identify additional relevant articles. The studies
have shown different cervical response and outcomes.13–18
In our previous study4 we found that 1000 micrograms of
self-administered vaginal misoprostol at home at least 12
hours prior to operative hysteroscopy was effective, safe
and acceptable for cervical priming in premenopausal but
not in postmenopausal women. We speculate whether a lack
of estrogen in postmenopausal women is the main reason
why misoprostol does not have a signiﬁcant cervical prim-
ing effect.
The mediators of the cervical ripening process are still
largely unknown. They have been studied in premenopausal
women19–23 and it has been demonstrated that local applica-
tion of prostaglandin E2 induces cervical ripening by in-
creased remodelling of the cervical connective tissue.21
Estrogen also enhances cervical ripening.23 Locally applied
estrogen is effective for vaginal atrophy in postmenopausal
women.24 It is probably necessary to treat postmenopausal
women who have not previously used hormone therapy with
dailylocallyappliedestrogenfor2weekstoachieveasufﬁcient
effect on the vaginal and urethral epithelium.25 There are no
published studies available on the effect of locally applied
estrogen on cervical tissue and epithelium. We have found
only one previous study that has investigated the ripening
effect of misoprostol on the estrogen-pretreated cervix in
postmenopausal women.18 The authors concluded that miso-
prostol alone was not effective for cervical ripening, but that it
was effective after 22 women had ﬁrst used estriol vaginal
cream for 14 days. However, the study was neither designed
nor conducted in accordance with the recommendations in
the CONSORT statement26 and lacked a sample size calcula-
tion with regards to evaluating primary outcome measures.
Furthermore, misoprostol was not compared to a placebo and
estriol cream was compared to clindamycine phosphate
cream.
The aim of our study is to investigate whether 1000
micrograms of self-administered vaginal misoprostol 12
hours before operative hysteroscopy results in effective pre-
operative cervical ripening after two weeks pre-treatment
with 25 micrograms daily vaginal estradiol, compared with
placebo (lactosum monohydricum) in postmenopausal
women.
Hypothesis
Null hypothesis: there is no clinically signiﬁcant difference in
preoperative baseline cervical dilatation (<1 mm), between
postmenopausal women who receive vaginal misoprostol
and postmenopausal women who receive vaginal placebo,
after pre-treatment with estradiol.
Interventions
All consecutive postmenopausal women (deﬁned at 1 year
after last menstruation) referred for day-care operative hys-
teroscopy, and who have given informed consent, will be
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study, but not using hormone therapy with estrogen, will start
daily treatment with estradiol vaginal tablets (Vagifem ,
Novo Nordisk, Ma ˚løv, Denmark, containing 25 micrograms
of estradiol per tablet) 2 weeks prior to the operation. The
effect of self-inserted 1000-microgram vaginal misoprostol 12
hours before operative hysteroscopy on cervical ripening will
be compared to self-inserted vaginal placebo 12 hours before
operative hysteroscopy.
Randomisation procedure
Thewomen will be assigned to either 1000-microgram vaginal
misoprostol or vaginal placebo. Full randomisation at
a ratio of 1:1 was created on 23 November 2007 with the
randomisation plan generator, as described by G. Dallal.27
The randomisation procedure is a third party concealed ran-
domisation, performed by the hospital pharmacist.
Outcome measures
Primary end-point
• The primary outcome is the preoperative baseline cervical
dilatation in the two treatment groups.
Secondary end-points
• Difference between baseline cervical dilatation at recruit-
ment, before treatment with estradiol, misoprostol or pla-
cebo, and preoperative dilatation.
• The number of women who achieve satisfactory cervical
priming (cervical dilatation ‡5 mm). Five millimetres is
chosen as ‘satisfactory’, as this would permit insertion
of a diagnostic hysteroscope without further dilatation. A
preoperative cervical dilatation of 5 millimetres would also
make it much easier to further dilate the cervix with Hegar
dilators if necessary, decreasing the risk of creating a false
passage.
• Acceptability of self-administration of vaginal capsules at
home.
• Number of dilatations judged as ‘easy’ or ‘difﬁcult’.
• Frequency of complications.
Number of women required
For ethical reasons it is important to keep the number of
women needed to reach a conclusion in clinical trials as low
as possible. A sequential trial plan using a two-sample sequen-
tial Wilcoxon test developed by Skovlund and Walløe is there-
fore used.28–30 This method has previously been used in
relatively few clinical trials, but has been shown to be easy
to use and robust. It is expected to reduce the number of
women needed to reach a conclusion, compared with the
number required in a corresponding ﬁxed sample trial.31,32
In our previous trial we needed only 20% of the sample size
before reaching a conclusion on postmenopausal women
using this method. The analysis was tailored to reach a con-
clusion on the primary outcome as soon as the difference was
signiﬁcant, so that as few women as possible were enrolled. A
trial with a ﬁxed sample size, with the same primary end-
point as ours, would have required 105 postmenopausal
women (SD 2.0) analysed in order to obtain a power of
95% based on a t test, assuming normally distributed obser-
vations and equal variance in the two groups. The boundaries
needed for the statistical model were calculated on the
preoperative variability (SD) in cervical dilatation from our
previous trial (Figure 1). The mean cervical dilatation was 4.2
millimetres, SD 2.0. The design of the main trial is based on
a signiﬁcance level of 5% and a power of 95% against a 1-
millimetre difference in the cervical dilatation caused by
misoprostol and placebo. As it seems unlikely that use of
misoprostol could cause a constriction of the cervix, a one-
sided test is chosen. Thetrial will continue until either the null
hypothesis or the alternative hypothesis has been refuted.
Following the sequential Wilcoxon test by Skovlund and Wal-
løe, the estimator of normal means is applied, if the observa-
tions are normally distributed.33
Eligibility criteria
Inclusion criteria: All postmenopausal (>1 year since last men-
struation) women who are referred to day-care hysteroscopy
with a medical indication for hysteroscopy, and who have
given informed consent, will be eligible for study recruitment.
Exclusion criteria: women who do not wish to participate,
women who are medically unﬁt for hysteroscopy, women
who are medically unﬁt for participation in any clinical trial,
women who do not have a medical indication for hystero-
scopy, women who have previously had, or currently have
breast or gynaecological cancer, women who have a medical
contraindication for locally applied estradiol, women who are
currently using hormone therapy, women who are unable to
communicate in Norwegian and women with a known allergy
to misoprostol.
Trial process and data collection
The present study protocol is designed according to the rec-
ommendations in the CONSORT statement26 and will be sub-
mitted to BJOG for review before recruitment of women. The
study is a randomised, controlled, double-blind one-centre
study at a Norwegian central university gynaecological out-
patients department. The study ﬂow (Figure 2) is planned as
follows:
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All women referred to day-care operative hysteroscopy at
Ulleva ˚l University Hospital in Oslo, Norway, will be sent an
invitation to be included in the study. Women are referred to
this hospital for operative hysteroscopy from private prac-
tising gynaecologists, GPs or other hospitals. The common
presenting complaints in postmenopausal women are post-
menopausal uterine bleeding and discovery of clinically silent
endometrial polyps. The invitation for study participation
will be sent together with dates for a preoperative outpatient
consultation. The study invitation will include detailed infor-
mation regarding the study, as well as an informed consent
form. The outpatient consultation will take place shortly after
the referral has been received. Here, the women will receive
additional information and be given the option to participate
in the study.
Allocation
M.L. will be responsible for examining women at the outpa-
tient consultation and for recruiting the women. Women who
elect to participate in the study, and who are not already using
estrogen hormone therapy, will receive estradiol vaginal
tablets daily for 2 weeks use prior to operative hysteroscopy,
as well as either 1000-microgram misoprostol or placebo
according to the randomisation list, to be self-inserted vagi-
nally at least 12 hours before operative hysteroscopy. Before
an endometrial biopsy and cervical smear is taken as part of
the routine preoperative examination, cervical dilatation
will be measured by passing Hegar dilators through the
cervix in ascending order starting with Hegar dilator of size
2 millimetres. No other tests will be taken for evaluation as
part of the trial, but serum haemoglobin, or other clinical
procedures, such as an electrocardiogram, may be ordered
as part of the routine preoperative examinations prior to
hysteroscopy.
The women will receive an appointment for their operation
at least 4 weeks after the initial outpatient consultation; the
length of the waiting period will depend on the suspected
diagnosis and the women’s symptoms and signs. Any
woman with a malignant histology result, or with clinical
symptoms and signs that strongly indicate a malignant dis-
ease will either be excluded from study participation upon
examination, or excluded as soon as the histology report is
presented (usually within a week). They will thus be pre-
vented from using either misoprostol or estrogen. Placebo
misoprostol tablets are difﬁcult to make, therefore the hos-
pital pharmacist will manufacture gelatine capsules with an
identical appearance. The active misoprostol will be ground
up as a whitish powder inserted into gelatine capsules (500-
microgram misoprostol per capsule), as well as an inactive
ingredient, lactosum monohydricum—which has an identi-
cal appearance to ground misoprostol tablets—and subse-
quently inserted into gelatine capsules as placebo. The
hospital pharmacist will thereafter prepare numbered, opa-
que, sealed plastic containers labelled ‘Misoprostol 0.5
mg/Placebo, 2 vaginal capsules’. The prepared capsules will
be inserted into containers by the hospital pharmacist, who
will then seal them with tamper-proof seals. Each container
will contain two capsules. Half of the containers will contain
two capsules with 500-microgram misoprostol each, while
the other half will contain two placebo capsules. The con-
tainers will then be delivered to the outpatients clinic. As the
women are recruited at the outpatient consultation, M.L.
will record the preoperative variables on a standardised case
reportform(onpage1)andthewomenwillbegivenaplastic
container containing the capsules. In addition, each woman
Figure 1. Continuation region of the sequential test. The stopping boundaries are shown. H0, boundary for the null hypothesis, HA, boundary for the
alternative hypothesis.
Oppegaard et al.
e3 ª 2008 The Authors Journal compilation ª RCOG 2008 BJOG An International Journal of Obstetrics and Gynaecologywill be given a prescription for 15 tablets of 25-microgram
estradiol to be collected at the hospital pharmacy. Hence,
those involved in administering the intervention and the
women will be blinded to the treatment received. Each study
participant will open a numbered container at home, con-
taining either misoprostol, or lactosum monohydricum in
capsules. The women will be instructed to begin inserting
one estradiol vaginal tablet daily 14 days before their oper-
ation. In addition, they will be instructed to insert the miso-
prostol/placebo capsules vaginally, as deep as possible, after
voiding urine at approximately 9 p.m. the evening before the
operation.
Follow up
On admission to the operating theatre, nurses will record
symptoms and comments from the women on the case report
form (page 1). The women will record pain experienced
betweentheinsertionofcapsulesandtheoperationonavisual
analogue scale score, ranging from 0 (no pain) to 10 (unbear-
able pain).
Women will be asked to rate acceptability of self-adminis-
tered capsules on a scale from 1 to 4 (1, completely acceptable;
2, fairly acceptable; 3, fairly unacceptable; 4, completely
unacceptable). The women will then be given a general
intravenous anaesthetic (propofol/fentanyl/alfentanyl) by the
attending nurse anaesthetist, after which the theatre nurses
will prepare the women for operation by disinfecting the
vulval and vaginal area with a 0.05% chlorhexidine acetate
solution (Fresenius Kabi, Halden, Norway). Visible vaginal
capsule remains will be noted before the area is irrigated.
The case report form with the preoperative variables, recorded
symptoms and comments from the women on page 1 will
then be turned over to page 2 so that this information is
Figure 2. Flow diagram.
PROTOCOL for the misoprostol, estradiol and operative hysteroscopy trial
ª 2008 The Authors Journal compilation ª RCOG 2008 BJOG An International Journal of Obstetrics and Gynaecology e4not available to either M.L. or the operating gynaecologist.
The operators will then be summoned to the operating
theatre. The women’s faces are hidden from the operators.
The operators should thus both be blinded to which treat-
ment the women had received and to the occurrence of
possible side effects from the treatment, as recorded by the
nurses.
Analysis
We will try to ensure that only a single gynaecologist performs
all the operative hysteroscopies. M.L. will instruct the opera-
tor as to how to correctly assess preoperative cervical dilata-
tion, so that they are in agreement with the measurement. We
hope that this might reduce subjectivity in gauging preoper-
ative cervical dilatation. During our previous trials, the use of
several gynaecologists assessing cervical dilatation may have
increased the risk of inter-observer variability. The use of
a single gynaecologist in this trial would reduce this interdoc-
tor assessment variation. Before the operative hysteroscopy,
the operator will measure the preoperative degree of cervical
dilatation by passing Hegar dilators through the cervix in
ascending order starting with a size of 2 millimetres. The size
of the largest dilator passed into the inner cervical ostium
without subjective resistance felt by the operator will be
recorded as the preoperative degree of dilatation. If there is
initial resistance with Hegar dilator of size 2 millimetres, the
result will be recorded as 0 millimetres. After the cervical
canal is dilated to a Hegar dilator of size 10 or 11 millimetres,
an Olympus (Olympus, Hamburg, Germany) rigid resecto-
scope model A22026A (Charriere 26) equipped with a Hop-
kins 12  rigid ﬁbreoptic model A22001A, will be passed into
the uterine cavity. A sodium chloride 9% solution (Baxter,
Norfolk, UK) will be infused for uterine irrigation. A bipolar
diathermal current of 280 watts (pure cut) supplied by a Surg-
master  US-40 (Olympus) diathermia unit will routinely be
used for resection of pathological uterine masses (myomas,
polyps, uterine septae etc.) and endometrium. For haemo-
stasis coagulation, a current of 80 watts will be applied.
Adverse events during the operation, such as superﬁcial cer-
vical lacerations, production of false passage of the cervix
during cervical dilatation and perforation of the uterus will
be recorded.
The case report form will then be delivered to K.S.O and
B.I.N. for separate and parallel analysis of the primary out-
come using the sequential method. In this case, crossing the
lower boundary will mean that misoprostol is signiﬁcantly
superior to placebo and crossing the upper boundary will
meanthatthetwotreatmentsareequallyeffective.Afteracon-
clusion has been reached on the primary outcome, K.S.O. and
M.L. will analyse the data for secondary outcomes, but with-
out performing signiﬁcance tests, because the trial is neither
designed nor powered for these.
Discontinuation
After recruitment, women may withdraw from the trial if they
do not wish to participate. They may decline to take the pre-
scribed estradiol vaginal tablets, misoprostol/placebo capsu-
les, or have the hysteroscopy itself. Side effects from vaginal
estradiol tablets are generally mild and well tolerated, but the
women may stop taking them if they feel that these are unac-
ceptable. (The misoprostol/placebo regimen is a once-only
dosage.) Acute illness would necessitate postponement of
the operation and would mean that the women would have
to be excluded from analysis.
Registering and reporting of suspected adverse
reactions
Any unexpected and serious preoperative side effects and sus-
pect adverse reactions will be immediately reported to K.S.O.
or B.I.N., as well as the trial steering committee (see the sec-
tion ‘Trial steering committee’). The Norwegian Medicines
Agency (SLV) and regional ethics committee will also be
notiﬁed. Procedure-related complications and side effects will
be continuously monitored and reported. The women will be
contacted by telephone–and the patient records will be
reviewed—after 14 days for registration of postoperative
complications.
Start date was 14 January 2008.
Expected completion date is 31 December 2008.
Data collection (variables)
Pre- intra-, and postoperative ﬁndings in the two treatment
groups.
Preoperative ﬁndings (recorded at preoperative consultation)
Vaginal placebo
(n 5 xx)
1000-microgram
vaginal misoprostol
(n 5 xx)
Age, height and weight
Parity
Years of menopause
No. births/previous
vaginal delivery
Previous cone biopsy
Baseline cervical dilatation
before treatment
Indications for operative
hysteroscopy
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Primary outcome
Sequential method by Skovlund and Walløe. See section
‘Number of patients required’.
Secondary outcomes
SPSS will be used to analyse secondary outcomes.
Publication policy
The study protocol will be sent to BJOG for peer review prior
to inclusion of women. The manuscript will be sent to BJOG
upon completion of the data analysis.
Trial steering committee
Bjørn Busund (Head of Department, Women and Children’s
Division, Ulleva ˚l University Hospital), Nina Kristoffersen
(Clinical Study Coordinator, Ulleva ˚l Hospital Pharmacy),
Eva Skovlund (Senior adviser, Norwegian Medicines Agency.
Professor II, University of Oslo).
Data monitoring and ethics committee
Ethical approval from The Regional Committee for
Medical Research Ethics (Regional komite ´ for medisinsk
forskningsetikk, Nord-Norge, REK Nord) in Northern
Norway34 was obtained on 16 October 2007 (Ref no.
200704112-5/MRO/400). Permission from the Norwegian
Medicines Agency35 (Statens Legemiddelverk, SLV) was
granted on 6 December 2007 (Ref no. 07/12515-8) and from
Ulleva ˚l Hospital’s Advisory Committee on the Protection of
Patient Records (Personvernansvarlig) on 17 December 2007.
The study protocol is published on http://www.clinicaltrials.
gov, and has been submitted to the European Clinical Trials
Database and BJOG. Each participating woman in the study
will sign an informed consent, and will be insured through the
Drug Liability Association (Legemiddelforsikringen) with lia-
bility insurance in connection with clinical trials of drugs.
Preoperative ﬁndings (recorded by nurse on the day of the operative
hysteroscopy prior to the operation)
Vaginal
placebo
(n 5 xx)
1000-microgram
vaginal misoprostol
(n 5 xx)
Duration of vaginal capsules
given before operation
(hours)
Preoperative side effects (e.g.
nausea, diarrhoea, vaginal
bleeding, cramps)
Pain measured on a visual
analogue scale score
0–10
Capsule treatment
acceptability (1 5
completely acceptable;
2 5 fairly acceptable;
3 5 fairly unacceptable;
4 5 completely
unacceptable)
Any comments from patient
Intraoperative ﬁndings (recorded by operating gynaecologist)
Vaginal
placebo
(n 5 xx)
1000-microgram
vaginal
misoprostol
(n 5 xx)
P
value
Markedly anteverted or
retroverted uterus
Median baseline cervical
dilatation (mm)
No. women achieving
preoperative cervical
dilatation 5m m
Dilatation time (minutes)
Dilatation difﬁcult (yes/no)
Complications (e.g.
cervical laceration, false
passage of the cervix,
uterine perforation)
Operative procedure
Difference in dilatation
before and after
administration of
estradiol and
misoprostol or placebo
Post-operative ﬁndings (recorded by one of the study authors)
Vaginal
placebo
(n 5 xx)
1000-microgram
vaginal
misoprostol
(n 5 xx)
P
value
Recorded postoperative
complications
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The Women’s Clinic at Ulleva ˚l University Hospital, Oslo,
Norway.
Funding source
No pharmaceutical company was involved in this study. The
funding sources will have no input into the study design,
collection, analysis or interpretation of the data, report prep-
aration or in the decision to submit the paper for publication.
K.S.O, M.L. and B.I.N. will have full access to all the data after
women no longer are being recruited into the study and will
have ﬁnal responsibility to submit manuscripts for publica-
tion.
A research grant from the regional research board of
Northern Norway has been awarded to ﬁnance Dr K.S.O.’s
leave from Hammerfest hospital as well as travel expenses
between Hammerfest and Oslo, and research courses. The
research grant from Prof B.I.N. (Helse Øst) will fund the
purchase of estradioltablets, the manufacturing costs of miso-
prostol and placebo capsules from the hospital pharmacy, as
well as the costs incurred for preparing the randomisation
schedule and distribution of containers containing capsules
to hospital. Prof B.I.N.’s research grant will also fund insur-
ance for the study participants.
Ulleva ˚l University Hospital’s personnel will send invita-
tions for study participation to the women and ensure that
the data collection is processed according to the recommen-
dations in the CONSORT statement.26
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e9 ª 2008 The Authors Journal compilation ª RCOG 2008 BJOG An International Journal of Obstetrics and GynaecologyDummy Table 1. Demographic characteristics of women in the two study groups according to dosage. Values are given as mean (SD) or n (%)
Characteristic Self-administered vaginal
placebo (n 5 xx)
Self-administered vaginal
misoprostol (n 5 xx)
Age (y)
BMI (kg/m2)
Years of menopause
Parity
Previous vaginal delivery
Previous cone biopsy
Dummy Table 2. Indications for operative hysteroscopy and operative procedure in the two study groups according to dosage
Indication Self-administered vaginal
placebo (n 5 xx)
Self-administered vaginal
misoprostol (n 5 xx)
Procedure
Dummy Table 3. Intraoperative ﬁndings and distribution of cervical dilatation in the two treatment groups. Values are given as mean (SD),
median (range) or n (%).
Dosage group
Self-administered vaginal placebo
(n 5 xx)
Self-administered vaginal misoprostol
(n 5 xx)
P
Cervical dilatation (mm) (n 5 xx)
Cervical dilatation (mm)
pre-menopausal (n 5 xx)
Cervical dilatation (mm)
post-menopausal (n 5 xx)
No. women achieving cervical
dilatation 5m m
‘Difﬁcult dilatation’
Dilatation time (seconds)
Dummy Table 4. Preoperative side effects in the two treatment groups and ﬁndings during treatment
Self-administered vaginal placebo
(n 5 xx)
Self-administered vaginal misoprostol
(n 5 xx)
Mean level of reported preoperative
pain* (SD)
Analgesic use n (%)
Complications n (%)
Occurrence of bleeding n (%)
Other possible side effects
*Measured with a VAS score, scale 0 (no pain)—100 unbearable pain.
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